度普利尤单抗(Dupixent)作为自免赛道的“药王”,2024年销售额达188.38亿美元,但面临国产IL-4Rα单抗的激烈竞争。康诺亚、先声药业、智翔金泰等多家中国药企已有多款IL-4Rα单抗处于上市申请或临床后期阶段,预计2026年将密集获批,对Dupixent形成围剿之势。Dupixent的成功源于精准卡位IL-4Rα靶点、全人源技术平台及前瞻性的适应症拓展,但未来增长面临不确定性。投资者...
Source Link度普利尤单抗(Dupixent)作为自免赛道的“药王”,2024年销售额达188.38亿美元,但面临国产IL-4Rα单抗的激烈竞争。康诺亚、先声药业、智翔金泰等多家中国药企已有多款IL-4Rα单抗处于上市申请或临床后期阶段,预计2026年将密集获批,对Dupixent形成围剿之势。Dupixent的成功源于精准卡位IL-4Rα靶点、全人源技术平台及前瞻性的适应症拓展,但未来增长面临不确定性。投资者...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.